Abstract Factor XI (FXI) deficiency is a rare inherited coagulation disorder characterized by infrequent spontaneous bleeding, but increased risk of hemorrhagic complications especially after trauma or surgery. Treatment options for FXI-deficient patients include virus-inactivated fresh frozen plasma, plasma-derived FXI concentrates, and activated recombinant FVII. Inhibitors of fibrinolysis, such as tranexamic acid, and desmopressin (DDAVP) have also been used in these patients, especially in mild cases. The current knowledge on the use of the latter agent in this congenital bleeding condition is systematically reviewed here. Although limited, the available literature data suggest the potential role of DDAVP for either treatment of bleeding episodes or the prevention of postoperative bleeding in patients with milder FXI defects. However, these findings need to be supported by further trials on large population of patients.
Introduction
Inherited factor XI (FXI) deficiency, originally named hemophilia C, is an uncommon autosomal recessive disorder, which is characterized by a more variable bleeding tendency than hemophilia A or B [1] [2] [3] [4] [5] [6] . Indeed, patients with severe FXI deficiency (plasma FXI activity [FXI:C] <15 U/dL) do not usually bleed spontaneously but may suffer excessive injury-or surgeryrelated bleeding [5] . In patients with milder defects (plasma FXI:C 15-60 U/dL), bleeding is, however, difficult to predict because it correlates poorly with FXI levels, thus making the clinical management of such patients particularly challenging [6] .
Replacement therapy with virally inactivated fresh frozen plasma (solvent-detergent-treated fresh frozen plasma (FFP)) or FXI concentrates is the mainstay of treatment of severe FXI deficiency, the latter one being, however, associated with an increased thrombotic risk [7] [8] [9] [10] . Activated recombinant factor VII has also been successfully used in patients with alloantibodies against FXI [11] [12] [13] . Antifibrinolytic agents such as tranexamic acid have been useful for the management of mild cases, for minor surgical procedures (e.g., tooth extraction), in severe FXI deficiency, or as an adjunct in more severe cases or procedures [14] . These drugs have also been used successfully in the management of women with FXI deficiency and menorrhagia [15, 16] . Desmopressin (DDAVP), a synthetic analog of the natural antidiuretic hormone vasopressin traditionally used in a variety of congenital and acquired bleeding disorders [17] [18] [19] , has also been recently administered in the prophylaxis of surgical bleeding in patients with partial symptomatic FXI deficiency [5] . The main advantages of this agent are safety, low cost, ease of use, and no risk of blood-borne virus transmission. In this review, we briefly summarize the available scientific literature on the role of DDAVP in the management of patients with FXI deficiency.
Search methods
We firstly performed an electronic search on MEDLINE, EMBASE, SCOPUS, OVID, and the Cochrane Library without temporal limits and using different combinations of the following keywords: "congenital haemophilia C", "factor XI deficiency", "FXI deficiency", "desmopressin", and "DDAVP". Only full-text articles with at least an English abstract were considered. The bibliographic references of all retrieved studies and reviews were assessed for additional reports of clinical trials. Unpublished works were identified by searching the abstract books of the most important meetings on this topic of the last 15 years (International Society on Thrombosis and Haemostasis, American Society of Hematology, European Hematology Association, World Federation of Hemophilia, Italian Society of Hematology). Overall, we identified 76 published references through the electronic (last access: 28 February 2009) and hand searches. After reading the full text of the articles/abstracts, we excluded 59 references focusing on other topics and retrieved 17 potentially relevant references for further assessment. A further nine studies were excluded because they were reviews. Thus, we have considered for this systematic review eight case series (seven full text articles and one abstract). The flowchart of the inclusion of the studies is reported in Fig. 1 . For statistical analysis, we used paired t tests. A P value <0.05 was considered significant.
Results
Only few case reports have been reported so far on the use of desmopressin for the treatment of bleeding or as surgical prophylaxis in patients with inherited deficiency of FXI [20] [21] [22] [23] [24] [25] [26] [27] . Castaman and colleagues [21] reported about two patients with partial FXI deficiency and previous bleeding histories who received DDAVP infusions before carpal tunnel surgery and dental extraction. The authors showed an increase of both FXI activity (16 and 23 U/dL, respectively) and antigen (FXI:Ag) levels (24 and 25 U/dL, respectively) 60 min after a DDAVP test infusion. A single DDAVP infusion was sufficient (in the patient undergoing dental extraction, it was associated with oral tranexamic acid) to provide an efficient perioperative hemostasis. As the authors also documented an immediate (30 min) rise of FXI levels after DDAVP infusion, they hypothesized a drug-induced release of FXI from storage compartment rather than increased synthesis as a leading mechanism of action. Interestingly, the investigators found an increase of FXI activity and antigen levels also in two normal subjects and type 1 von Willebrand disease (VWD) patients. Their results were supported by a previous doubleblind, placebo-controlled crossover study published by Agnelli and colleagues [28] in patients with chronic liver disease. The authors found a 22% increase of FXI:C levels after DDAVP infusion (0.5 μg/kg). However, these findings were not replicated by a more recent study by White and colleagues [29] , who failed to found any significant increase of FXI:C and FXI:Ag levels in 33 individuals with VWD or mild hemophilia A. The lack of rise of FXI:C levels after DDAVP infusion was also observed by De Angelis and colleagues [20] in a patient with combined factor VIII (FVIII) and FXI deficiency. These contradictory results may reflect methodological differences among the various case reports. Alternatively, the response to DDAVP infusion could be genetically determined, thus depending on the type of mutation causing the FXI defect. It is also conceivable that the beneficial effect of DDAVP in such cases could depend on the pronounced increase in the levels of VWF and FVIII rather than to the slight rise of FXI.
The successful use of DDAVP for the prevention of bleeding in a patient with a mild FXI defect undergoing a neurosurgery operation was reported by Bauduer and colleagues [22] . The largest experience in this field has been described by our group [23] . Indeed, we reported six patients with a heterozygous defect FXI:C levels, ranging from 32 to 45 U/dL, undergoing various surgical procedures under hemostatic coverage with DDAVP and antifibrinolytic agents. A DDAVP test produced a slight increase of FXI:C levels (median 12 U/dL, range 9-14 U/ dL) after subcutaneous injection. No bleeding complications or drug-related adverse effects were documented.
Studies identified (n=76)
Excluded (n=59): other topics
Potentially relevant studies (n=17)
Case series with usable information included in the analysis (n=8) Excluded (n=9): reviews Fig. 1 Flowchart of the inclusion of the studies Heim and colleagues [25] reported a 9-year-old girl with FXI deficiency (basal FXI:C 8%) with postoperative bleeding which was stopped after DDAVP infusion. Interestingly, DDAVP was associated with an increase in FXI:C up to 31%. No adverse events were recorded. We recently published two additional cases [27] : Subcutaneous injection of DDVP was effective in preventing postoperative bleeding in two patients with heterozygous FXI deficiency and multinodular goiter undergoing total thyroidectomy. Ruiz-Saez and colleagues [26] reported the successful use of DDAVP in a patient with combined FXI deficiency and VWD. Finally, in a double-blind crossover study, Kadir and colleagues [30] randomized 39 women with menorrhagia and inherited bleeding disorders (two patients with FXI deficiency and three with combined VWD and FXI deficiency) to start 2 months' therapy with placebo or DDAVP spray (300 μg). No previous DDAVP response was assessed. No statistically significant difference (P=0.5) in pictorial blood assessment chart scores was observed in women receiving DDAVP than in those receiving placebo.
The case series reporting the use of DDAVP in FXIdeficient patients are summarized in Table 1 . Overall, 16 cases have been reported so far in the literature. The ratio male/female was 1.5, while the median age was 35.2 years (range 4-67 years). Although DDAVP was used also in four children without adverse events, we advise particular caution when administering this agent in young patients due to its antidiuretic effects. Table 1 shows that in the majority of cases, DDAVP was used for the management of minor bleeding episodes or surgical procedures. However, in a few cases, this agent was used to prevent postoperative bleeding in major surgeries. The median increase of FXI:C levels following the administration of DDAVP was statistically significant (basal FXI:C levels 34.5 U/dL [range 1-4 U/dL] versus 47.9 U/dL [range 1-60 U/dL] 1 h after DDAVP administration, P<0.01). The median number of doses of DDAVP administered was 3.7 (range 1-5 doses) and the median number of days of therapy was 3.5 (rang 1-5 days). However, these ranges are too wide, so that definitive evidences about doses and duration of DDAVP therapy in this clinical setting are yet to be established. In half of the cases, antifibrinolytic agents were associated with DDAVP therapy. As antifibrinolytic agents have a confirmed efficacy alone in some surgical procedures [31] , this concomitant therapy could mask the real efficacy of DDAVP in congenital FXI-deficient patients. In most cases (14/16, 87.5%), DDAVP was used as prophylaxis of surgical-related bleeding. The majority of these patients (12/14, 85.7%) had a positive family or personal bleeding history, which justified the prophylactic use of this agent. However, it is also possible that preventive treatment with DDAVP was unnecessary and that such patients would not have bled without treatment, as recently reported by Salomon and colleagues [32] . Indeed, the authors retrospectively analyzed bleeding manifestations related to vaginal and/or cesarean deliveries in 62 women with severe FXI deficiency and concluded that the use of FFP is not mandatory in such patients, but it can be reserved for cases with excessive bleeding. Nevertheless, DDAVP appeared to be safe and effective in the cases series reported as no bleeding complications or drug-related adverse events occurred.
Conclusions
Overall, the published literature data suggest the potential role of DDAVP for both management of bleeding episodes and surgical prophylaxis in patients with milder congenital FXI defects. However, as these findings are only supported by few case reports, proper trials on large patient population are needed to definitely assess the efficacy of this agent in the management of FXI deficiency. Further studies will also help to elucidate the biological effect of DDAVP in FXI deficiency since the literature results are conflicting in relation to the FXI levels achieved.
